TACR1 and insomnia measurement: The case for indication-specific dosing of NK1R antagonists has been previously discussed [39, 40], e.g., while partial receptor occupancy was sufficient to see improvement in insomnia, nearly 100 % occupancy may be required to see an effect in major depression [39], though a mechanistic rationale for these windows is still absent.